How has investor appetite in health technology evolved throughout the years? In this blog post we examine the total investments by year into this sector to help answer that question. The graph below shows the total number of investors in all deals stacked by quarters.
As the graphic demonstrates, investor activity in health technology has remained steady in recent years. The 5-Year CAGR of healthtech investor activity from 2013 to 2018 is 11%. In addition, the sector has seen a total of 930 investors in all deals through Q2 of this year. This represents 48% of the total investor activity in 2018, and 87% of the investor activity through Q2 in 2018. Taking all these data points together, we can see that investor appetite for health technology deals is levelling off in recent years.
How has the exit activity for health technology developed in the first half of 2019? This blog post explores health technology exit metrics through Q2 2019 and compares them to previous years. The graph below shows the number of health technology exits by year, stacked by quarters.
As the graphic demonstrates, health technology has seen a total of 37 exit events through Q2 of this year. This represents 56% of the total exits in 2018, and 88% of the exits through Q2 in 2018. Some of the exit events in Q2 2019 include Exonics Therapeutics’ acquisition by Vertex Pharmaceuticals, PatientsLikeMe’s acquisition by the UnitedHealth Group, and Beyond Meat’s IPO.
A straight-line projection of the completed exit activity this year would come out to 74 exit events, which exceeds the total exits in 2018 by 12%. On the other hand, a weighted quarterly average projection of 2019 exit activity would come out to 58 exit events, which falls short of the total exits in 2018 by 12%. Therefore, based on the mid-year data, health technology exit activity in 2019 is projected to be relatively equal to the exit activity in 2018.
How is the funding environment shaping up for health technology in 2019? As we pass the mid-year mark, let’s see how the year-to-date metrics compare to the historical trends. The graph below shows health technology total funding by year, stacked by quarters.
As the graphic demonstrates, health technology has amassed $9.4B through Q1 and Q2 of this year. This amount represents 51% of the total funding in 2018, and 105% of the funding through Q2 in 2018. In addition, the top three funding events in Q2 2019 include a $300M round into Impossible Foods, a $205M round into Collective Health, and a $190M round into Zipline.
A straight-line projection of the completed funding this year would result in $18.9B, which is 103% of the total 2018 funding. On the other hand, a weighted quarterly average projection of 2019 funding would result in $19.3B, which exceeds the total 2018 funding by 5%. Therefore, based on the mid-year data, health technology funding in 2019 is projected to surpass the funding in 2018.
The health technology industry has seen 3,918 investors and $90B total all time funding. Let’s analyze which health technology categories have the most number of investors actively financing the startups. The graphic below highlights health technology categories based on the number of investors in each category.
As the graphic demonstrates, Digital Medical Devices has the highest number of investors at 1077, with IoT Health Care following behind at 810. Digital Medical Device companies build IT-enabled medical and diagnostic devices for doctors. IoT Health Care companies create connected devices that track health metrics or help improve health well-being. In addition, the average number of investors across all health technology categories is 374.
For this quarter’s funding analysis, let’s examine how average funding in the health technology sector is evolving. The graphic below shows the health technology average funding across all deals over time by quarter.
As the graphic demonstrates, health technology average funding deal size in Q1 2019 was at $42M, which increased by 30% from the $32M last quarter. The average funding deal size has demonstrated strong upward growth, with the average funding last quarter around 5 times larger than it was 5 years ago. The top three funding events in Q1 2019 include a $1B round into Verily, a $500M round into Clover Health, and a $299M round into BridgeBio.